STELLEST, EXPLAINED

The first FDA-cleared myopia control lens. The data is serious.

Essilor's Stellest made history in September 2025 when it became the first myopia-control spectacle lens authorized by the FDA. That "first" matters. It means the lens went through the agency's review process with clinical trial data the FDA found convincing — a bar no competitor had cleared before.

The numbers come from a two-year US clinical trial. Children wearing Stellest showed 71 percent less myopia progression and 53 percent less axial elongation compared to the control group. Axial elongation is the key metric — it's the physical lengthening of the eyeball that drives worsening nearsightedness. Slowing it by more than half is the kind of result that gets an entire industry's attention.

How does it work? Stellest uses a constellation of tiny lenslets — over a thousand of them — arranged across the lens surface. They create a volume of myopic defocus in front of the retina while the center of the lens corrects vision normally. The theory: that defocus signal tells the growing eye to slow down. Kids see clearly through the middle and get the treatment signal in the periphery, all day, just by wearing their glasses.

Stellest is the established, cleared, data-backed option in the US market. If you're an American parent hearing about myopia control for the first time, this is likely the name your eye doctor mentions first. There's a reason.

*Talk to your eye doctor: Stellest is FDA-cleared, but clearance doesn't mean it's right for every child — ask if your kid is a candidate and what the follow-up schedule looks like.*

"71% less progression. 53% less eye growth. Those numbers changed the conversation."